Portfolio Receipts of $742 million in Q4 2024 and $2,801 million for FY 2024Royalty Receipts growth of 12% in Q4 2024 and 13% for FY 2024 Net ...

Appointment Deepens Financial and Operational Expertise of Boardas Company Approaches Potential CommercializationSOUTH SAN FRANCISCO, Calif., ...

When it comes to investing in pharmaceutical companies, looking at pipelines and research and development prospects is ...

Portfolio Receipts of $742 million in Q4 2024 and $2,801 million for FY 2024Royalty Receipts growth of 12% in Q4 2024 and 13% for FY 2024 Net cash provided by operating activities of $743 million in ...

CEO Richard Francis reflects on Teva’s return to growth during his tenure, and what’s next for the drugmaker in its quest to ...

With shifting employee expectations around wellbeing, support and work-life balance, and a more generationally diverse workforce, it’s clear that traditional hierarchical leadership models – where ...

This co-marketing initiative underscores both companies' commitment to expanding market reach without requiring additional capital investment. By integrating QHSLab’s digital health capabilities into ...

For example, Brittany found that drugs being developed by Generate were modified versions of existing antibodies, and that ...

Not all advertising executives share his sangfroid. Today, technology is changing the industry faster than at any time since ...

With a rumored $8m price tag, the Super Bowl ad stakes are high – but the potential brand rewards are massive. How can ...

The two positive studies mean that Boehringer can now seek approval for nerandomilast with a broad label claim in pulmonary ...

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.